TALEN® for Best-In-Class Gene Editing
Cellectis leverages its leadership in gene editing through its flagship technology, TALEN®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies. TALEN® has been successfully used in the clinic to solve key challenges with allogeneic CAR T including protection from Graft vs. Host Disease, mitigation of rejection and enhanced safety via the integration of a suicide switch.
"Off-the-shelf" immunotherapies
that can work for the largest number of patients
Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients. It’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in designing therapies for many other diseases.
Strong intellectual property,
global strategic partnerships.
24 years of innovation. more than 100 patent families. 300 granted patents and 200 applications. Global strategic partnerships with Allogene, Servier, Iovance, Primera and AstraZeneca